Alan S. Robertson

Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects

Karen L. Houseknecht, Alan S. Robertson, William J. Zavadoski et al. · Neuropsychopharmacology · 2006 · 240 citations

Obesity, Metabolic Syndrome, Whole-body Insulin Resistance +13

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 114 citations · Full text

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Meihua Tu, Kevin J. Filipski et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 44 citations · Full text

Medicinal Chemistry, Diabetes Management, Biochemistry +11

Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents

Alan S. Robertson, Mark J. Majchrzak, Courtney M. Smith et al. · Neuromuscular Disorders · 2017 · 40 citations · Full text